This chapter contains sections titled: Introduction Questions Literature‐search strategy and inclusion Should patients with DLBCL receive involved‐field radiation as part of primary therapy? Should patients with a good response to chemotherapy who are at high risk for recurrence receive consolidation with autologous stem cell transplantation? Should rituximab be added to second‐line therapy for patients with relapsed disease? Should patients with advanced DLBCL receive dose‐dense chemotherapy supported by growth factors? Should older patients with DLBCL receive CHOP chemotherapy with curative intent? References Introduction Questions Literature‐search strategy and inclusion Should patients with DLBCL receive involved‐field radiation as part of primary therapy? Should patients with a good response to chemotherapy who are at high risk for recurrence receive consolidation with autologous stem cell transplantation? Should rituximab be added to second‐line therapy for patients with relapsed disease? Should patients with advanced DLBCL receive dose‐dense chemotherapy supported by growth factors? Should older patients with DLBCL receive CHOP chemotherapy with curative intent? References